Palvella Therapeutics reports positive phase 3 trial results for rare disease Feb 24, 2026 06:30AM
Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations Feb 24, 2026 06:30AM
Palvella schedules call to discuss Phase 3 trial results for skin gel Feb 23, 2026 05:00PM
Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malf Feb 23, 2026 05:00PM
Palvella Therapeutics publishes systematic review on statin use in porokeratosis Feb 2, 2026 07:30AM
View Older Stories

Feb 2, 2026 07:30AM Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting f
Jan 9, 2026 07:30AM Palvella plans March 2026 data readout for rare skin disease drug
Jan 9, 2026 07:30AM Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with
Jan 7, 2026 07:30AM Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs
Dec 16, 2025 07:30AM Palvella Therapeutics receives FDA fast track designation for angiokeratoma treatment
Dec 16, 2025 07:30AM Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Angiokeratomas
Dec 15, 2025 06:00AM Palvella reports positive Phase 2 results for rare skin disease treatment
Dec 15, 2025 06:00AM Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malform
Nov 11, 2025 07:30AM Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Nov 6, 2025 07:30AM Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference
Nov 5, 2025 06:00AM Palvella announces new drug candidate for rare skin disease
Nov 5, 2025 06:00AM Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous
Nov 4, 2025 07:30AM Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025
Oct 13, 2025 07:30AM FDA awards Palvella second year of orphan drug grant for rare disease trial
Oct 13, 2025 07:30AM U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics’ Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformat
Sep 24, 2025 06:01AM Palvella expands QTORIN rapamycin development to angiokeratomas
Sep 24, 2025 06:00AM Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved The
Sep 17, 2025 07:33AM Palvella announces scientific publication on rapamycin for venous malformations
Sep 17, 2025 07:30AM Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as
Sep 15, 2025 07:30AM Palvella Therapeutics completes enrollment in phase 2 trial for rare skin condition
Sep 15, 2025 07:30AM Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations
Sep 3, 2025 07:31AM Palvella appoints David Osborne as chief innovation officer
Sep 3, 2025 07:30AM Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer
Aug 28, 2025 07:30AM Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences
Aug 14, 2025 07:30AM Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Aug 7, 2025 07:30AM Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025
Aug 5, 2025 07:30AM Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
Jun 30, 2025 07:30AM Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes
Jun 23, 2025 07:30AM Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%
Jun 18, 2025 07:30AM Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors
Jun 9, 2025 07:30AM Palvella Therapeutics (PVLA) Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN
Jun 9, 2025 07:30AM Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations
May 27, 2025 08:05AM Palvella Therapeutics (PVLA) Appoints Ashley Kline as Chief Commercial Officer
May 27, 2025 08:00AM Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer
May 15, 2025 07:30AM Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 8, 2025 07:30AM Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025
May 5, 2025 07:30AM Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025
Apr 23, 2025 04:15PM Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual
Apr 22, 2025 07:30AM Palvella Therapeutics (PVLA) Granted Additional U.S. Patent for QTORIN Rapamycin for the Treatment of Microcystic Lymphatic Malformations
Apr 22, 2025 07:30AM Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
Apr 11, 2025 07:30AM Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermat
Apr 4, 2025 08:00AM Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference
Apr 2, 2025 08:00AM Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology
Mar 31, 2025 07:30AM Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
Mar 18, 2025 08:30AM Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025
Feb 25, 2025 08:00AM Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference
Feb 10, 2025 08:00AM Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the You
Jan 10, 2025 08:05AM Palvella Therapeutics (PVLA) Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations in the Jour
Jan 10, 2025 08:00AM Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformati
Jan 8, 2025 08:00AM Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations
View Older Stories